RT Journal Article
SR Electronic
T1 Therapeutic application of alpha-1-antitrypsin in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.02.21252580
DO 10.1101/2021.04.02.21252580
A1 Felix Ritzmann
A1 Praneeth Chitirala
A1 Yiwen Yao
A1 Nadine Krüger
A1 Markus Hoffmann
A1 Wei Zuo
A1 Frank Lammert
A1 Sigrun Smola
A1 Nastasja Seiwert
A1 Naveh Tov
A1 Noga Alagem
A1 Bahareh Mozafari
A1 Katharina Günther
A1 Martina Seibert
A1 Sabrina Hörsch
A1 Thomas Volk
A1 Philipp M. Lepper
A1 Guy Danziger
A1 Stefan Pöhlmann
A1 Christoph Beisswenger
A1 Christian Herr
A1 Robert Bals
YR 2021
UL http://medrxiv.org/content/early/2021/04/06/2021.04.02.21252580.abstract
AB Rationale The treatment options for COVID-19 patients are sparse and do not show sufficient efficacy. Alpha-1-antitrypsin (AAT) is a multi-functional host-defense protein with anti-proteolytic and anti-inflammatory activities.Objectives The aim of the present study was to evaluate whether AAT is a suitable candidate for treatment of COVID-19.Methods AAT and inflammatory markers were measured in the serum of COVID-19 patients. Human cell cultures were employed to determine the cell-based anti-protease activity of AAT and to test whether AAT inhibits the host cell entry of vesicular stomatitis virus (VSV) particles bearing the spike (S) protein of SARS-CoV-2 and the replication of authentic SARS-CoV-2. Inhaled and / or intravenous AAT was applied to nine patients with mild-to-moderate COVID-19.Measurements and Main Results The serum AAT concentration in COVID-19 patients was increased as compared to control patients. The relative AAT concentrations were decreased in severe COVID-19 or in non-survivors in ratio to inflammatory blood biomarkers. AAT inhibited serine protease activity in human cell cultures, the uptake of VSV-S into airway cell lines and the replication of SARS-CoV-2 in human lung organoids. All patients, who received AAT, survived and showed decreasing respiratory distress, inflammatory markers, and viral load.Conclusion AAT has anti-SARS-CoV-2 activity in human cell models, is well tolerated in patients with COVID-19 and together with its anti-inflammatory properties might be a good candidate for treatment of COVID-19.Funding This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, the BMBF, the State of Lower Saxony, and The State of Saarland.Scientific Knowledge on the Subject COVID-19 is caused by “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) and is a serious global health threat. Efficacious treatments are not available and there are no drugs that can prevent progression towards respiratory and extra-pulmonary organ failure. AAT has been studied in vitro and has activity against SARS-CoV-2. We searched PubMed and Google Scholar using the search terms “COVID-19”, “SARS-CoV-2”, “therapy”, and “α-1-antitrypsin” (AAT) for research published in 2020 and 2021.What This Study Adds to the Field This study shows the results of a translational program with a focus on the biology of AAT in COVID-19. The data show that there is a relative deficiency of AAT in relation to systemic inflammation. AAT inhibits serine protease activity in human airway cells and the replication of SARS-CoV-2 in human lung organoids. Inhaled and / or intravenous application of AAT in nine patients was associated with clinical stabilization. The findings of this exploratory study suggest that AAT has a mechanistic role in the pathophysiology of COVID-19 based on its anti-inflammatory and anti-viral activities. This offers the possibility to test and develop AAT application for treatment of different phenotypes or stages of COVID-19, including severe, inflammatory courses or early stages. Inhaled treatment could be an option to administer AAT non-invasively in early stages.Competing Interest StatementDr. Bals reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from Grifols, grants and personal fees from Novartis, personal fees from CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from Sander Stiftung, grants from Schwiete Stiftung, grants from Krebshilfe, grants from Mukoviszidose eV, outside the submitted work. Naveh Tov is an employee of Kamada Ltd. Naveh Tov is an inventor on the following provisional patent applications: USP 62/994,898 filed Mar. 26. 2020, US 63/017,703 filed Apr. 30, 2020 Noga Alagem is an employee of Kamada Ltd. The other authors report no conflict of interest.Clinical TrialNCT04799873Funding StatementFunding: This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, the BMBF, the State of Lower Saxony, and The State of Saarland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients for observational measurements of AAT serum levels were recruited within the COVID-19 cohort study CORSAAR (n = 35) and its control cohort PULMOHOM. Both studies have been approved by the ethics committee of the Landesaerztekammer Saarland, and all patients or their legal representatives gave their informed consent. This approach was reported to the ethics committee of the Aerztekammer des Saarlandes. The use of human cells was approved by the ethics committee of the Landesaerztekammer of the Saarland and informed consent was obtained from the patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected for the study, including individual participant data and a data dictionary defining each field in the set, will be made available to others upon reasonable request. The data that will be made available include anonymized clinical data and data dictionaries. Other related documents are available, including the study protocol, statistical analysis plan, informed consent. The data will be available with publication through the email of the corresponding author. Data will be shared after approval by the author group.